These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16597397)

  • 1. [From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
    Foretz M; Guigas B; Viollet B
    Med Sci (Paris); 2006 Apr; 22(4):348-50. PubMed ID: 16597397
    [No Abstract]   [Full Text] [Related]  

  • 2. LKB1: a sweet side to Peutz-Jeghers syndrome?
    Carling D
    Trends Mol Med; 2006 Apr; 12(4):144-7. PubMed ID: 16530014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
    Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
    Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
    Shaw RJ; Lamia KA; Vasquez D; Koo SH; Bardeesy N; Depinho RA; Montminy M; Cantley LC
    Science; 2005 Dec; 310(5754):1642-6. PubMed ID: 16308421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicine. Cancer-suppressing enzyme adds a link to type 2 diabetes.
    Marx J
    Science; 2005 Nov; 310(5752):1259. PubMed ID: 16311305
    [No Abstract]   [Full Text] [Related]  

  • 6. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
    Foretz M; Hébrard S; Leclerc J; Zarrinpashneh E; Soty M; Mithieux G; Sakamoto K; Andreelli F; Viollet B
    J Clin Invest; 2010 Jul; 120(7):2355-69. PubMed ID: 20577053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase.
    Huypens P; Quartier E; Pipeleers D; Van de Casteele M
    Eur J Pharmacol; 2005 Aug; 518(2-3):90-5. PubMed ID: 16039647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer research. Cancer prevention with a diabetes pill?
    Taubes G
    Science; 2012 Jan; 335(6064):29. PubMed ID: 22223788
    [No Abstract]   [Full Text] [Related]  

  • 9. Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice.
    Sakakibara S; Yamauchi T; Oshima Y; Tsukamoto Y; Kadowaki T
    Biochem Biophys Res Commun; 2006 Jun; 344(2):597-604. PubMed ID: 16630552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More TORC for the gluconeogenic engine.
    Cheng A; Saltiel AR
    Bioessays; 2006 Mar; 28(3):231-4. PubMed ID: 16479585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.
    Forcet C; Etienne-Manneville S; Gaude H; Fournier L; Debilly S; Salmi M; Baas A; Olschwang S; Clevers H; Billaud M
    Hum Mol Genet; 2005 May; 14(10):1283-92. PubMed ID: 15800014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMP-activated protein kinase: Role in metabolism and therapeutic implications.
    Schimmack G; Defronzo RA; Musi N
    Diabetes Obes Metab; 2006 Nov; 8(6):591-602. PubMed ID: 17026483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
    McCarty MF
    Med Hypotheses; 2005; 64(6):1211-5. PubMed ID: 15823720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
    Algire C; Amrein L; Bazile M; David S; Zakikhani M; Pollak M
    Oncogene; 2011 Mar; 30(10):1174-82. PubMed ID: 21102522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2/STAT5 signalling pathway.
    Zhang X; Zhuang Y; Qin T; Chang M; Ji X; Wang N; Zhang Z; Zhou H; Wang Q; Li JZ
    Metabolism; 2021 Sep; 122():154823. PubMed ID: 34197875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism.
    Jansen M; Ten Klooster JP; Offerhaus GJ; Clevers H
    Physiol Rev; 2009 Jul; 89(3):777-98. PubMed ID: 19584313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation.
    Kyriakis JM
    J Biol; 2003; 2(4):26. PubMed ID: 14575531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo.
    Collins SP; Reoma JL; Gamm DM; Uhler MD
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):673-80. PubMed ID: 10642527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
    Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes.
    Musi N; Goodyear LJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):119-27. PubMed ID: 12476786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.